{
    "clinical_study": {
        "@rank": "87503", 
        "acronym": "ENESTswift", 
        "arm_group": {
            "arm_group_label": "Nilotinib", 
            "arm_group_type": "Experimental", 
            "description": "300mg BD of nilotinib being evaluated after non-haematological intolerance to dasatinib or imatinib in CML."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of nilotinib 300mg twice\n      daily in patients with chronic myeloid leukemia chronic phase who are intolerant but\n      responsive to 1st line treatment with imatinib or dasatinib. Eligible patients have been\n      previously treated with imatinib or dasatinib for at least 3 months and are experiencing\n      non-hematologic toxicity whilst having documented responses that meet PBS authority for 1st\n      line treatment of CML without current MR4.5."
        }, 
        "brief_title": "Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Philidelphia Positive Chronic Myeloid Leukaemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Eastern Cooperative Oncology Grou (ECOG) Performance Status of 0, 1, or 2.\n\n          2. Patient with diagnosis of Ph+ CML-CP associated with BCR-ABL quantifiable by RQ-PCR\n             (IS).\n\n          3. Patient has received a minimum of 3 months of imatinib or dasatinib treatment (any\n             dose) since initial diagnosis with a documented response.\n\n          4. Patient is eligible for Pharmaceutical Benefits Scheme (PBS) reimbursed 1st line TKI\n             treatment.\n\n          5. Patient has experienced non-hematological Adverse Events (AE(s)) of any grade, which\n             persisted for at least 1 month despite supportive care or recurred at any grade at\n             least once.\n\n          6. No other current or planned anti-leukemia therapies.\n\n          7. Adequate organ function.\n\n          8. Potassium, Magnesium and Total Calcium above Lower limit of normal.\n\n        Exclusion Criteria:\n\n          1. Prior treatment with nilotinib.\n\n          2. Prior Accelerated Phase (AP), Blast Crisis (BC) or allogeneic-transplant (unless the\n             patient received an autologous transplant and was in Chrionic Phase (CP) prior to\n             transplant and never in AP or BC).\n\n          3. Patient has failed prior 1st line treatment in terms of the PBS reimbursement\n             criteria.\n\n          4. Patient has documented Molecular Response (MR) 4.5 at the time of study entry\n\n          5. Patients with atypical BCR-ABL transcript not quantifiable by standard RQ-PCR.\n\n          6. Known impaired cardiac function.\n\n          7. Impairment of gastrointestinal (GI) function or GI disease that may significantly\n             alter the absorption of study drug.\n\n          8. Pregnant or nursing (lactating) women.\n\n          9. Women of child-bearing potential unwilling or unable to use highly effective\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108951", 
            "org_study_id": "CAMN107AAU04"
        }, 
        "intervention": {
            "arm_group_label": "Nilotinib", 
            "description": "Nilotinib 300 mg BD will be prescribed by the Investigator for use under the Pharmaceutical Benefits Scheme (PBS) as per standard practice. Patients will be instructed on compliance and asked to complete compliance questionnaires at each visit.", 
            "intervention_name": "Nilotinib", 
            "intervention_type": "Drug", 
            "other_name": "Tasigna, AMN107"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CML", 
            "Ph-CML", 
            "leukaemia", 
            "leukemia", 
            "chronic myeloid leukemia"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Canberra", 
                        "country": "Australia", 
                        "state": "Australian Capital Territory", 
                        "zip": "2606"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kogarah", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2217"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2170"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nambour", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4560"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Box Hill", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3168"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nedlands", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Single Arm Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Intolerant to Prior Tyrosine Kinase Inhibitors (TKIs)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": [
            {
                "affiliation": "Novartis Pharmaceuticals", 
                "last_name": "Novartis Pharmaceuticals", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Royal Adelaide Hospital", 
                "last_name": "Timothy Hughes, MD, FRACP, FRCPA", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Human Research Ethics Committee", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Outcome measured by confirmed (2 consecutive) bcr-abl levels at MR4.5 by central laboratory prior to the 24 month treatment point.", 
            "measure": "Percentage of patients with MR4.5 at 24 months", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108951"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Outcome measured by confirmed (2 consecutive) bcr-abl levels at MMR or MR4.0 by central laboratory prior to the 24 month treatment point.", 
                "measure": "Proportion of patients with MMR or MR4.0 at 24 months", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Logistic regression of MR4.5 within 24 months with duration of prior TKI therapy as a continuous covariate confirmed by central laboratory.", 
                "measure": "Duration of prior TKI therapy for those patients achieving MR4.5 within 24 months, and for those patients not achieving MR4.5 within 24 months.", 
                "safety_issue": "No", 
                "time_frame": "24 months."
            }, 
            {
                "description": "Using baseline BCR-ABL concentrations to determine time to MR4.5 for those patients that reach the primary outcome. As confirmed by central laboratory.", 
                "measure": "Logistic regression of MR4.5 within 24 months with baseline BCR-ABL ratio categories", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}